Vindesine and mitomycin c in metastatic breast cancer

Alan P. Lyss, Susan L. Luedke, Lawrence Einhorn, Dan W. Luedke, Marilyn Raney

Research output: Contribution to journalArticle

5 Scopus citations


64 eligible women with previously treated metastatic breast cancer received mitomycin C plus vindesine chemotherapy. Dosage was based on investigators' estimate of patients' bone marrow reserve. There were 19 evaluable patients in the good marrow reserve category, with two complete and three partial responses (26%). In the poor marrow reserve category there were 29 evaluable patients with four partial responses (14%). The 26% response rate in patients with good marrow reserve is consistent with results obtained with this and similar combinations by other investigators.

Original languageEnglish (US)
Pages (from-to)357-359
Number of pages3
JournalOncology (Switzerland)
Issue number6
StatePublished - Jan 1 1989


  • Breast cancer
  • Metastatic breast cancer
  • Mitomycin c
  • Refractory breast cancer
  • Vindesine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Vindesine and mitomycin c in metastatic breast cancer'. Together they form a unique fingerprint.

  • Cite this

    Lyss, A. P., Luedke, S. L., Einhorn, L., Luedke, D. W., & Raney, M. (1989). Vindesine and mitomycin c in metastatic breast cancer. Oncology (Switzerland), 46(6), 357-359.